A Phase Ⅱ Study Assessing the Safety and Efficacy of PLB1004 in EGFR ex20ins Mutation Patients With Advanced and Metastatic Non-small Cell Lung Cancer(NSCLC)

PHASE2RecruitingINTERVENTIONAL

Enrollment

157

Participants

Timeline

Start Date

July 21, 2023

Primary Completion Date

March 6, 2025

Study Completion Date

October 30, 2025

Conditions

Non-Small-Cell Lung Cancer

Interventions

DRUG

PLB1004

PLB1004 is a capsule in the form of 80mg and 40mg.

Trial Locations (1)

RECRUITING

Guangdong General Hospital, Guangzhou

All Listed Sponsors

lead

Avistone Biotechnology Co., Ltd.

INDUSTRY